Cannabis-Derived Pharmaceuticals
Requires Subscription or Fee PDF




Cannabis, commonly known as marijuana, weed or pot, is a natural product derived from the Cannabis sativa plant. It has been used medicinally for thousands of years. Recent legislation allowing the use of medical marijuana in over 23 US states has spurred interest in developing pharmaceutical-derived Cannabis products to treat a variety of clinical indications ranging from pain relief to epilepsy.  Many products are in late stage clinical development in the US and elsewhere.  This article reviews the medicinal properties of Cannabis and describes pharmaceutical-derived Cannabis products that are currently being developed for theUS market.
Requires Subscription or Fee PDF


Russo EB. (2007) History of cannabis and its preparations in saga, science, and sobriquet. Chemistry &Biodiversity 4(8):1614-1648.

Schultes RE. (1992) Plants of the gods: their sacred, healing and hallucinogenic powers. Rochester, New York: Healing Arts Press.

Iversen L. The science of marijuana. (2000) Oxford, England: Oxford University Press

Corey S. (2005) Recent developments in the therapeutic potential of cannabinoids. Puerto Rico Health Sciences Journal 24(1):19-26.

Alexander A, Smith PF, Rosengren RJ. (2009) Cannabinoids in the treatment of cancer. Cancer Letters 285(1):6-12.

Aizpurua-Olaizola O, Omar J, Navarro P, Olivares M, Etxebarria N, Usobiaga A. (2014) Identification and quantification of cannabinoids in Cannabis sativa L. plants by high performance liquid chromatography-mass spectrometry. Analytical and Bioanalytical Chemistry 406(29):7549-7560.

Bowles DW, O'Bryant CL, Camidge DR, Jimeno A. (2012) The intersection between cannabis and cancer in the United States. Critical Reviews in Oncology/Hematology 83(1):1-10.

Pacher P, Batkai S, Kunos G. (2006) The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacological Reviews 58(3):389-462.

Pacher P, Kunos G. (2013) Modulating the endocannabinoid system in human health and disease--successes and failures. The FEBS Journal 280(9):1918-1943.

Elphick MR, Egertova M. (2001) The neurobiology and evolution of cannabinoid signalling. Philosophical transactions of the Royal Society of London. Series B, Biological Sciences 356(1407):381-408.

Grotenhermen F. (2005) Cannabinoids. Current Drug Targets CNS And Neurological Disorders 4(5):507-530.

Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI.(1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346(6284):561-564.

Guindon J, Hohmann AG. (2008) Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain. British Journal of Pharmacology 153(2):319-334.

Fernandez-Ruiz J, Pazos MR, Garcia-Arencibia M, Sagredo O, Ramos JA. (2008) Role of CB2 receptors in neuroprotective effects of cannabinoids. Molecular and Cellular Endocrinology 286(1-2 Suppl 1):S91-96.

Anand P, Whiteside G, Fowler CJ, Hohmann AG. (2009) Targeting CB2 receptors and the endocannabinoid system for the treatment of pain. Brain Research Reviews 60(1):255-266.

Pertwee RG, Ross RA. (2002) Cannabinoid receptors and their ligands. Prostaglandins, Leukotrienes, and Essential Fatty Acids 66(2-3):101-121.

Rahn EJ, Hohmann AG. (2009) Cannabinoids as pharmacotherapies for neuropathic pain: from the bench to the bedside. Neurotherapeutics: The Journal Of The American Society For Experimental Neurotherapeutics 6(4):713-737.

Gerra G, Zaimovic A, Gerra ML, et al. (2010) Pharmacology and toxicology of Cannabis derivatives and endocannabinoid agonists. Recent patents on CNS drug discovery 5(1):46-52.

Mechoulam R, Gaoni Y. (1965) A Total Synthesis of Dl-Delta-1-Tetrahydrocannabinol, the Active Constituent of Hashish. Journal of the American Chemical Society 87:3273-3275.

Hazenkamp A, Gortenhermen F (2010) Review on clinical studies with cannabis and cannabinoids 2005-2009. Cannabinoids 5(special issue):1-21.

Hill AJ, Weston SE, Jones NA, et al. (2010) (Delta (9)-Tetrahydrocannabivarin suppresses in vitro epileptiform and in vivo seizure activity in adult rats. Epilepsia 51(8):1522-1532.

Hill AJ WC, Whalley BJ, Spehens GJ. (2012) Phytocannabinoids as novel therapeutic agents in CNS disorders Pharmacology & therapeutics 133:79-97.

Jones NA, Hill AJ, Smith I, et al. (2010) Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo. The Journal of Pharmacology And Experimental Therapeutics 332(2):569-577.

Russo E, Guy GW. (2006) A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Medical Hypotheses 66(2):234-246.

Zuardi AW, Shirakawa I, Finkelfarb E, Karniol IG.( 1982) Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology 76(3):245-250.

Bisogno T, Hanus L, De Petrocellis L, et al. (2001) Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. British Journal Of Pharmacology 134(4):845-852.

Bornheim LM, Grillo MP. (1998) Characterization of cytochrome P450 3A inactivation by cannabidiol: possible involvement of cannabidiol-hydroxyquinone as a P450 inactivator. Chemical Research in Toxicology 11(10):1209-1216.

Cilio MR, Thiele EA, Devinsky O.(2014) The case for assessing cannabidiol in epilepsy. Epilepsia 55(6):787-790.

Deiana S. (2013) Medical use of cannabis. Cannabidiol: A New Light For Schizophrenia? Drug Testing and Analysis 5(1):46-51.

Cridge BJ, Rosengren RJ. (2013) Critical appraisal of the potential use of cannabinoids in cancer management. Cancer Management and Research 5:301-313.

Cascio MG, Gauson LA, Stevenson LA, Ross RA, Pertwee RG. (2010) Evidence that the plant cannabinoid cannabigerol is a highly potent alpha2-adrenoceptor agonist and moderately potent 5HT1A receptor antagonist. British Journal of Pharmacology 159(1):129-141.

Colasanti BK. (1990) A comparison of the ocular and central effects of delta 9-tetrahydrocannabinol and cannabigerol. Journal of Ocular Pharmacology 6(4):259-269.

Borrelli F, Fasolino I, Romano B, et al. (2013) Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease. Biochemical Pharmacology 85(9):1306-1316.

Dos Santos RG, Hallak JE, Leite JP, Zuardi AW, Crippa JA. (2014) Phytocannabinoids and epilepsy. Journal of Clinical Pharmacy and Therapeutics

Granja AG, Carrillo-Salinas F, Pagani A, et al. (2012) A cannabigerol quinone alleviates neuroinflammation in a chronic model of multiple sclerosis. Journal Of Neuroimmune Pharmacology: The Official Journal of The Society on Neuroimmune Pharmacology 7(4):1002-1016.

Maione S, Piscitelli F, Gatta L, et al. (2011) Non-psychoactive cannabinoids modulate the descending pathway of antinociception in anaesthetized rats through several mechanisms of action. British Journal of Pharmacology 162(3):584-596.

Shinjyo N, Di Marzo V. (2013) The effect of cannabichromene on adult neural stem/progenitor cells. Neurochemistry International 63(5):432-437.

Amada N, Yamasaki Y, Williams CM, Whalley BJ. (2013)Cannabidivarin (CBDV) suppresses pentylenetetrazole (PTZ)-induced increases in epilepsy-related gene expression. Peer J. 1:e214.

Scutt A, Williamson EM. (2007) Cannabinoids stimulate fibroblastic colony formation by bone marrow cells indirectly via CB2 receptors. Calcified Tissue International 80(1):50-59.

Karniol IG, Shirakawa I, Takahashi RN, Knobel E, Musty RE. (1975) Effects of delta9-tetrahydrocannabinol and cannabinol in man. Pharmacology 13(6):502-512.

McCallum ND, Yagen B, Levy S, Mechoulam R. (1975) Cannabinol: a rapidly formed metabolite of delta-1- and delta-6-tetrahydrocannabinol. Experientia 31(5):520-521.

Mahadevan A, Siegel C, Martin BR, Abood ME, Beletskaya I, Razdan RK. (2000) Novel cannabinol probes for CB1 and CB2 cannabinoid receptors. Journal of Medicinal Chemistry 43(20):3778-3785.

Petitet F, Jeantaud B, Reibaud M, Imperato A, Dubroeucq MC. (1998) Complex pharmacology of natural cannabinoids: evidence for partial agonist activity of delta9-tetrahydrocannabinol and antagonist activity of cannabidiol on rat brain cannabinoid receptors. Life Sciences 63(1):1-6.

Hazenkamp A GF. (2010) Review on clinical studies with cannabis and cannabinoids 2005-2009. Cannabinoids 5(special issue):1-21.

Giacoppo S, Mandolino G, Galuppo M, Bramanti P, Mazzon E. (2014) Cannabinoids: new promising agents in the treatment of neurological diseases. Molecules 19(11):18781-18816.

Lynch ME, Campbell F. (2011) Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials. British Journal of Clinical Pharmacology 72(5):735-744.

Zajicek JP, Apostu VI. (2011) Role of cannabinoids in multiple sclerosis. CNS Drugs 25(3):187-201.

Zajicek JP, Hobart JC, Slade A, Barnes D, Mattison PG, Group MR. (2012) Multiple sclerosis and extract of cannabis: results of the MUSEC trial. Journal of Neurology, Neurosurgery, and Psychiatry 83(11):1125-1132.

GW Pharma (2003). Cannabis-based medicines--GW pharmaceuticals: high CBD, high THC, medicinal cannabis--GW pharmaceuticals, THC:CBD. Drugs in R&D 4(5):306-309.

Barnes MP. (2006) Sativex: clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain. Expert Opinion on Pharmacotherapy 7(5):607-615.

Maa E, Figi P. (2014) The case for medical marijuana in epilepsy. Epilepsia 55(6):783-786.

Gloss D, Vickrey B. (2014) Cannabinoids for epilepsy. The Cochrane Database of Systematic Reviews 3:1-23.

GW Pharma (2014) GW Pharmaceuticals announces that Sativex receives fast track designation from FDA in cancer pain. Accessed April 9, 2015

Guzman M, Duarte MJ, Blazquez C, et al. (2006) A pilot clinical study of Delta9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. British Journal of Cancer 95(2):197-203.

Notcutt W, Price M, Miller R, et al (2004). Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 'N of 1' studies. Anaesthesia 59(5):440-452.

Tramer MR, Carroll D, Campbell FA, Reynolds DJ, Moore RA, McQuay HJ. (2001) Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ 323(7303):16-21.

Pisanti S, Malfitano AM, Grimaldi C, et al. (2009) Use of cannabinoid receptor agonists in cancer therapy as palliative and curative agents. Best Practice & Research. Clinical Endocrinology & Metabolism 23(1):117-131.

Salazar M, Carracedo A, Salanueva IJ, et al. (2009) Cannabinoid action induces autophagy-mediated cell death through stimulation of ER stress in human glioma cells. The Journal of Clinical Investigation 119(5):1359-1372.

Caffarel MM, Andradas C, Mira E, et al. (2010) Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition. Molecular Cancer 9:196.

Qamri Z, Preet A, Nasser MW, et al. (2009) Synthetic cannabinoid receptor agonists inhibit tumor growth and metastasis of breast cancer. Molecular Cancer Therapeutics 8(11):3117-3129.

Flygare J, Sander B. (2008) The endocannabinoid system in cancer-potential therapeutic target? Seminars in cancer biology 18(3):176-189.

National Center for Pharmacoeconomics-Ireland (2014) Cost-effectiveness of Delta-9-tetrahydrocannabinol/cannabidiol (Sativex®) as add-on treatment, for symptom improvement in patients with moderate to severe spasticity due to MS

Lu L, Pearce H, Roome C, Shearer J, Lang IA, Stein K.(2012) Cost effectiveness of oromucosal cannabis-based medicine (Sativex(R)) for spasticity in multiple sclerosis. PharmacoEconomics 30(12):1157-1171.

Doblin RE, Kleiman MA. (1991) Marijuana as antiemetic medicine: a survey of oncologists' experiences and attitudes. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 9(7):1314-1319.

Charuvastra A, Friedmann PD, Stein MD. (2005) Physician attitudes regarding the prescription of medical marijuana. Journal of Addictive Diseases 24(3):87-93.

Unless specified by prior arrangement, the author agrees to the following terms and assurances:

  1. For myself and on behalf of the other authors listed on this work, I assign to thinkBiotech LLC the copyright* in the contribution for the full term throughout the world.
  2. I/we further give to the following assurances
    1. I am the sole author of the contribution, or, if not, I have the written authority of the other authors to transfer the copyright* to thinkBiotech LLC and give these warranties;
    2. I and (where appropriate) the other authors are entitled to transfer the copyright to thinkBiotech LLC and no one else would be entitled to prevent us from publishing the contribution;
    3. To the best of my/our knowledge, all the facts in the contribution are true and accurate;
    4. The content of the contribution is entirely original to me (and where appropriate to the other authors) or, if not, the written permission of the owner of the copyright in any material copied from elsewhere has been obtained for all media (all such permissions to be attached to the contribution as supplementary files);
    5. Nothing in the contribution is obscene or libellous;
    6. Nothing in the contribution infringes any duty of confidentiality which I/or the other authors may owe to anyone else.
    7. I and/or the other authors have obtained the appropriate clearances from my/our employer(s) or other concerned institution(s).
* Works by US government employees prepared as part of official duties are in the public domain and the authors are therefore exempt from copyright assignment.